Stanford
http://www.stanfordgroup.com/#Stanford provides institutional investment services and private wealth management services. The firm also offers equity research to its clients in the consumer, media, energy, financial, healthcare, technology and water/environment sectors.
View Older Stories View More Recent Stories
-
Cytokinetics (CYTK) Reports Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy
-
Innovate Biopharma (INNT) Appoints Saira Ramasastry to Board; Announces Resignation of Anna Kazanchyan M.D. from Board
-
ATARA Biotherapeutics (ATRA) Publishes New Research Linking Epstein-Barr Virus Infection and Multiple Sclerosis
-
AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018
-
Arcus Biosciences (RCUS) Announces Promotion of Jennifer Jarrett to COO
-
China Online Education Group Announces First Quarter 2018 Results
-
Cytokinetics (CYTK) Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at SMA Conf.
-
ATARA Biotherapeutics (ATRA) Announces Appointment of Utpal Koppikar as CFO
-
QS World University Rankings 2019: MIT Named World’s Best University for Record-Breaking Seventh Consecutive Year
-
Deckers Outdoor (DECK) Appoints Two New Independent Directors
-
eHealth (EHTH) Names Derek N. Yung as Chief Financial Officer
-
Kilroy Realty (KRC) Reports Acquisition of Life Science Development Site in South San Francisco
-
Galectin Therapeutics (GALT) Reports Election of Richard E. Uihlein as Board Chairman
-
Versartis (VSAR) Reports Merger Agreement with Aravive Biologics
-
Jazz Pharmaceuticals (JAZZ) Announces Long-Term Safety & Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol
-
Jazz Pharmaceuticals (JAZZ) Reports Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients
-
Pfizer (PFE) Reports Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA (trastuzumab)
-
PayPal (PYPL) Acquires Jetlore
-
Nike Tennis Camps Returns to Stanford University Summer 2018 Led by Head Coach Lele Forood
-
Riot Blockchain (RIOT) Announces Strategic Investment in The Block
-
Krystal Biotech (KRYS) Granted FDA Fast Track Designation for KB103 for Treatment of Dystrophic Epidermolysis Bullosa
-
Stanford Graduate School of Business Recognizes Students Committed to Social Innovation
-
Atlas Air Worldwide Holdings (AAWW) Announces Election of Jane H. Lute and Sheila A. Stamps to Board
-
Stanford Self-Made Millionaire Comes to LA to Shoot Documentary
-
Form 4 Energy XXI Gulf Coast, For: May 17 Filed by: SPRINGEL STANFORD
-
Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatm
-
Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatm
-
Fibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy
-
Stanford Leadership Summer Camp Draws Students from Around the World
-
Abeona Therapeutics (ABEO) Updates Clinical Data from Phase 1/2 Trial for EB-101 Gene Therapy in Epidermolysis Bullosa
-
Aileron Therapeutics (ALRN) CEO Resigns
-
Abeona Therapeutics (ABEO) Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
-
NMI Holdings (NMIH) COO Claudia Merkle Promoted to President
-
Krystal Biotech (KRYS) Reports First Patient Dosing in Phase 1/2 trial of KB103
-
Rexford Industrial Realty (REXR) Acquires 2 Industrial Properties for $127.1M; Reports Sale of 2 Properties for $9.1M
-
Audentes Therapeutics (BOLD) Names Natalie Holles President and COO
-
Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis
-
Jazz Pharmaceuticals (JAZZ) Reports Supplemental NDA Filling for Xyrem (sodium oxybate)
-
Medtronic (MDT) Announces FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory
-
TransDigm Group (TDG) Names Kevin Stein as President and CEO and W. Nicholas Howley as Executive Chairman
-
Krystal Biotech (KRYS) Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
-
AveXis (AVXS) Reports First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
-
AveXis (AVXS) Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1
-
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at AAN
-
PolarityTE (COOL) Names Willie Bogan to Board
-
Rexford Industrial Realty (REXR) Appoints Diana Ingram To Board Of Directors
-
Stanford University School of Medicine Presents Results of Research Partnership with Gen Nine in Clinical Study of CosmosVue
-
Cisco Systems (CSCO) Announces Mark Garrett to Board
-
Natera (NTRA) Names Paul R. Billings, M.D., Ph.D., as Chief Medical Officer
-
PriceSmart (PSMT) Names Maarten Jager as EVP & CFO

